2023-05-08 17:25
Annual General Meeting of Infant Bacterial Therapeutics
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 8, 2023, among other things, the following was resolved: implementation...
Message from the CEO Significant advancements have been made in the development of microbiome-based pharmaceuticals in the past few months. Ferring/Rebiotics'...
2023-04-03 11:20
Notice of Annual General Meeting of Infant Bacterial Therapeutics
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Annual General Meeting to be...
2023-03-22 21:30
Infant Bacterial Therapeutics publishes Annual Report for 2022
Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2022. The report is available on IBT´s website, ibtherapeutics.com...
2023-03-22 10:31
Infant Bacterial Therapeutics’ (IBT) opening of a final infant cohort will accelerate patient recruitment
IBT is pleased to announce today's opening of the additional cohort, having included 1,400 premature infants of the total 2,158 recruitment target. Up...
2023-02-10 08:00
Infant Bacterial Therapeutics AB (publ) Interim report January 1- December 31, 2022
Message from the CEO The speed of recruitment of preterm infants into our large phase 3 study significantly increased in the final three months of 2022...
On March 31 2022 IBT published the 2021 annual report in the format of a PDF file. Today, IBT publish the same report in the XHTML format. The content...
The ‘Connection Study’ on the pharmaceutical grade probiotic IBP-9414 has two independent primary endpoints- the incidence of Necrotizing Enterocolitis...
2023-01-12 10:13
IBT secures platform for pharma grade probiotic to prevent antibiotic resistant hospital acquired infections
Building upon the company's unique expertise in developing pharma grade probiotics, Infant Bacterial Therapeutics AB (IBT) has secured an exclusive global...
2022-11-10 08:00
Infant Bacterial Therapeutics AB (publ) (IBT), Interim Management Statement, July 1 – September 30, 2022
Message from the CEO Our IBP-9414 clinical phase III development project is progressing well, and as previously mentioned, we are pursuing several initiatives...